For HCPs, Request Your Two-week Kardia 12L Trial Today | Inquire Now

AliveCor Logo

Our Technology

Our Devices

Kardia 12L

New

KardiaMobile 6L
K1000 (InstantQT)
Our Personal EKGs

Our Software

KardiaPro
KardiaStation
KardiaComplete
KardiaCare Plus
API & SDK Solutions
Our AI

Our Solutions

For Health Systems & Providers

For Life Sciences Industry

Clinical Trials
Patient Engagement
For Employers
For Veterans Affairs
For Payors
For Consumers

About

Mission
Leadership
The Human Component Film
Newsroom
Clinical Evidence
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Handheld 6-Lead Validated for QT Monitoring

JAMAnetwork.com

In this diagnostic study, a standard 12-lead ECG measurement was compared to a 6-lead device in a tuberculosis trial. Performed in South Africa, the study assessed 191 participants. Triplicate reference standard 12-lead ECG results were human calibrated with readers blinded to 6-lead ECG results.

At a QTc interval threshold of 500 milliseconds, the 6-lead device had a high negative predictive value of 99.8%.

This study suggests that simplified, handheld 6-lead ECG devices are effective triage tests that could reduce the need to perform standard 12-lead ECG monitoring in resource-constrained settings.

Key Takeaways:

  • At a diagnostic cut point of 500 milliseconds, 98.8% of clinic visits (483 of 489) were correctly classified by the handheld 6-lead device:
    • 482 as true negatives (ie, QTc interval <500 milliseconds measured by both devices)
    • 1 as true positive (ie, QTc interval of ≥500 milliseconds measured by both devices)
  • In resource-limited settings where QT screening is needed, the 6-lead device can be a cost-effective (20-50 times less costly than the conventional ECG), efficient, and reliable triage tool, resulting in more patient-centered care
  • There is proven diagnostic accuracy, repeatability, and feasibility with the 6-lead device

Read Full Article

Clinical Evidence

Handheld 6-Lead Validated for QT Monitoring

JAMAnetwork.com | A 6-lead device transforms cardiac care in resource-limited settings. This study in JAMA highlights its accuracy in monitoring QT intervals, reducing standard 12-lead ECG dependency, and easing access to cardiac care.

Remote Monitoring in Decentralized Trials

JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.

KardiaMobile® 6L vs 12-lead ECG Impact on Clinic Time

Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12-lead ECG systems. This study published in Wiley highlights how KardiaMobile 6L minimizes the need for frequent conventional 12-lead use.